Subsequently, the FDA approved programmed cell death protein 1 (PD-1) inhibitor nivolumab for the treatment of advanced melanoma due to its favorable overall survival, durable tumor remission after drug discontinuation, and acceptable long-term safety [9, 10]. This evidence concerns the gene PDCD1 and neoplasm.